NI
SUPN icon

NDVR Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

NDVR Inc’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$242K Buy
4,873
+549
+13% +$26.7K 0.2% 85
2025
Q3 		$207K Buy
+4,324
New +$174K 0.17% 111

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NDVR Inc's SUPN Position: Q4 2025 in Review

NDVR Inc increased its Supernus Pharmaceuticals (SUPN) stake by 13% in Q4 2025, buying an estimated $26.7K and bringing the position to 4,873 shares worth $242K. The position accounts for 0.2% of the portfolio, ranked #85.

NDVR Inc first reported a position in SUPN in Q3 2025 and has held it in 2 quarters since. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • NDVR Inc held 4,873 shares of Supernus Pharmaceuticals worth $242K as of Q4 2025.
  • NDVR Inc bought 549 Supernus Pharmaceuticals shares in Q4 2025, an estimated $26.7K.
  • Supernus Pharmaceuticals made up 0.2% of NDVR Inc's portfolio in Q4 2025, its #85 holding.
  • NDVR Inc first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on NDVR Inc's 13F filing for Q4 2025, filed 12 Feb 2026.